Skip to main content

Table 1 Demographic, clinical, and laboratory data of breast cancer patients with IORT and non-IORT

From: The impact of intraoperative radiotherapy on breast cancer: focus on the levels of angiogenic factors

Variables Non-IORT (n = 229) IORT (n = 131) p
Age 50 ± 63 51 ± 31 NS
Tumor side (%)    NS
Right 116 (78.5) 62 (47.3)  
Left 113 (21.5) 69 (52.7)  
Family history (%)    0.01
Negative 176 (76.8) 85 (65.5)  
Positive 53 (23.2) 46 (34.5)  
Histology (%)    NS
IDC 176 (76.8) 99 (75.5)  
ILC 35 (15.3) 20 (15.3)  
DCIS 14 (6.2) 11 (8.3)  
Other types 4 (1.7) 1 (0.8)  
ER (%)    0.01
Negative 86 (37.5) 33 (25.2)  
Positive 143 (62.5) 98 (74.8)  
PR (%)    NS
Negative 89 (38.9) 43 (32.8)  
Positive 140 (61.1) 88 (67.2)  
HER-2 (%)    NS
Negative 141 (67.3) 91 (71.7)  
Positive 66 (32.7) 36 (28.3)  
Tumor grade (%)    NS
I (well differentiation) 26 (11.4) 18 (13.7)  
II (mod differentiation) 119 (51.9) 80 (61.1)  
III (poor differentiation) 84 (36.7) 33 (25.2)  
Vascular invasion (%)    NS
Negative 147 (64.2) 95 (72.5)  
Positive 82 (35.8) 36 (27.5)  
Perineural invasion (%)    NS
Negative 198 (86.5) 112 (85.5)  
Positive 31 (13.5) 19 (14.5)  
Calcification (%)    NS
Negative 185 (83.7) 114 (87.0)  
Positive 36 (16.3) 17 (13.0)  
Necrosis (%)    NS
Negative 170 (76.4) 95 (72.5)  
Positive 51 (23.6) 36 (27.5)  
Pathological T stage (%)    NS
T1 (≤ 2 cm) 100 (43.6) 64 (48.8)  
T2 (> 2 cm, ≤ 5 cm) 120 (52.4) 67 (51.2)  
T3 (> 5 cm) 9 (3.9) 0 (0)  
Pathological N stage (%)    NS
N0 122 (53.3) 83 (63.4)  
N1 (1–3) 59 (25.7) 29 (22.1)  
N2 (4–9) 23 (10.1) 12 (9.2)  
N3 ≥ 10 25 (10.9) 7 (5.3)  
TNM stage (%)    NS
0 14 (6.1) 11 (8.5)  
I 52 (22.7) 41 (31.8)  
II 105 (45.8) 57 (44.2)  
III 56 (24.4) 20 (15.5)  
IV 2 (1.0) 0 (0)  
  1. Values are presented as mean ± standard deviation or number (%). IORT intraoperative radiation therapy, DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, TNM tumor, node, and metastasis